Immedica Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
4
- Investments
-
5
Immedica Pharma General Information
Description
Distributor of specialty pharmaceuticals intended to help in metabolic diseases, oncology, and ophthalmology. The company offers marketing, regulatory affairs, market access, and distribution services, enabling healthcare providers to access medicines for genetic, metabolic, hematology, and oncology conditions.
Contact Information
Website
www.immedica.comCorporate Office
- Solnavagen 3H
- 113 63 Stockholm
- Sweden
Corporate Office
- Solnavagen 3H
- 113 63 Stockholm
- Sweden
Immedica Pharma Timeline
Immedica Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immedica Pharma Comparisons
Industry
Financing
Details
Immedica Pharma Competitors (2)
One of Immedica Pharma’s 2 competitors is Bluefish Pharmaceuticals, a Private Equity-Backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bluefish Pharmaceuticals | Private Equity-Backed | Stockholm, Sweden | ||||
| Chiesi Nordic | Corporation | Stockholm, Sweden |
Immedica Pharma Patents
Immedica Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023254828-A1 | Treatment of arginase 1 deficiency | Pending | 11-Apr-2022 | ||
| EP-4508207-A1 | Treatment of arginase 1 deficiency | Pending | 11-Apr-2022 | ||
| EP-4508207-A4 | Treatment of arginase 1 deficiency | Pending | 11-Apr-2022 | ||
| JP-2025513844-A | Treatment of arginase 1 deficiency | Pending | 11-Apr-2022 | ||
| US-20250228921-A1 | Treatment of arginase 1 deficiency | Pending | 11-Apr-2022 | A61K38/50 |
Immedica Pharma Signals
Immedica Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immedica Pharma Investments (5)
Immedica Pharma’s most recent deal was a Buyout/LBO with Neurocrine UK for . The deal was made on 21-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neurocrine UK | 21-Jan-2026 | Buyout/LBO | Drug Delivery | ||
| Marinus Pharmaceuticals | 07-Feb-2025 | Buyout/LBO | Drug Discovery | ||
| Aeglea BioTherapeutics (Pegzilarginase Assets) | 27-Jul-2023 | Buyout/LBO | Buildings and Property | ||
| Novartis (Rights for Ophthalmology Products) | 01-Oct-2019 | Buyout/LBO | Other Pharmaceuticals and Biotechnology | ||
| Medical Need | 27-Jul-2018 | Buyout/LBO | Pharmaceuticals |
Immedica Pharma Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Immedica Pharma Germany | Dusseldorf, Germany | 2019 | |
| Medical Need | Stockholm, Sweden | 2011 | |
| Neurocrine UK | Cardiff, United Kingdom | 2004 |
Immedica Pharma FAQs
-
When was Immedica Pharma founded?
Immedica Pharma was founded in 2018.
-
Where is Immedica Pharma headquartered?
Immedica Pharma is headquartered in Stockholm, Sweden.
-
What is the size of Immedica Pharma?
Immedica Pharma has 200 total employees.
-
What industry is Immedica Pharma in?
Immedica Pharma’s primary industry is Pharmaceuticals.
-
Is Immedica Pharma a private or public company?
Immedica Pharma is a Private company.
-
What is Immedica Pharma’s current revenue?
The current revenue for Immedica Pharma is .
-
How much funding has Immedica Pharma raised over time?
Immedica Pharma has raised $216M.
-
Who are Immedica Pharma’s investors?
Kohlberg Kravis Roberts, Impilo, and Belnord Capital have invested in Immedica Pharma.
-
Who are Immedica Pharma’s competitors?
Bluefish Pharmaceuticals and Chiesi Nordic are competitors of Immedica Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process